2seventy bio (TSVT) to Release Earnings on Tuesday

2seventy bio (NASDAQ:TSVT) is scheduled to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

2seventy bio (NASDAQ:TSVT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. 2seventy bio had a negative return on equity of 66.01% and a negative net margin of 354.16%. The business had revenue of $8.97 million for the quarter, compared to analysts’ expectations of $11.43 million. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Stock Performance

NASDAQ TSVT opened at $4.73 on Friday. The stock has a market cap of $243.60 million, a price-to-earnings ratio of -1.54 and a beta of 1.78. The business has a 50 day simple moving average of $4.76 and a 200 day simple moving average of $4.50. 2seventy bio has a 52-week low of $1.53 and a 52-week high of $6.40.

Insiders Place Their Bets

In other news, insider Jessica Snow sold 7,816 shares of 2seventy bio stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $4.32, for a total value of $33,765.12. Following the sale, the insider now directly owns 156,330 shares in the company, valued at $675,345.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lowered their price objective on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.